Visual Matrix Expands in the Middle East, Partnering With the Best Western Premier M Four Hotel in Dubai to Provide Advanced Property Management Solutions
The hotel is Visual Matrix's first property in Dubai, 1st in the Middle East region and 225th outside North America.
Full Property Management, Front Desk and Mobile Housekeeping Benefits
Under the new partnership, the Best Western Premier M Four Hotel will gain access to:
Real-time visibility between housekeeping and front-desk operations. Hotel operations teams never have to question the status of a room, and team members can prioritize welcoming new guests.
Labor savings and efficiency. Hotels are more efficient using MOP, and leveraging the tool allows hotel staff members to work faster, save labor hours, and reduce errors or mistakes.
Built-in emergency panic buttons designed to empower staff at all times. These panic buttons are available on every screen of the MOP application, and when pressed automatically alert designated staff members and security.
Integrated texting system allowing two-way communication between hotel workers and guests.
'Choosing the right technology to operate your hotel is crucially important and can be tied to any property's success, which is why we are excited to partner with Visual Matrix to leverage their industry-leading PMS to manage our operations,' said Ravi Nair, General Manager of the Best Western Premier M Four Hotel. 'We were initially in the market for a new Best Western-approved PMS, which led us to Visual Matrix. Our team is looking forward to this technology–and the relationship–going forward.'
The 175-room Best Western Premier M Four Hotel is located in the heart of Deira, the historic center of Dubai. Guests of the hotel will have access to two international restaurants, complemented by a rooftop shisha cafe.
'We are excited to partner with the Best Western Premier M, a four-star hotel located in the heart of Deira, to provide its operations team with a cutting-edge property management system designed to help reduce friction, improve communication and connect with guests,' said Georgine Muntz, CEO of Visual Matrix. 'Through our collaboration, the Best Western Premier M will have the tools it needs to provide unparalleled service and stand out in the city of the World.'
For more information on Visual Matrix, visit visualmatrix.com.
About Visual Matrix
More than 3,000 properties in 30+ countries worldwide choose the Visual Matrix hospitality operating platform to optimize hotel operations and serve guests from reservation to return stay. Our system includes a game-changing PMS supported by powerful features and key integrations that are easy to use, including revenue management with automated rate tiering, a fully integrated channel manager, and a mobile app for tracking performance on the go. The Visual Matrix MOP housekeeping and maintenance tool automates routine tasks and streamlines communication to keep the front desk, housekeeping, and maintenance staff focused on guests It also includes a built-in panic button as an Emergency Safety Device (ESD) to help keep hotel staff from harm. For more information, visit visualmatrix.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 days ago
- Bloomberg
Rewriting India's investment playbook: Why portfolio management services are taking the lead
From niche to mainstream: the new face of PMS The evolution of Portfolio Management Services has been nothing short of remarkable. The PMS of today bears little resemblance to the opaque, high-touch but low-tech offerings of the past. As Anand Shah, CIO – PMS and AIF Investments at ICICI Prudential Asset Management Co., explains, the modern client expects more. 'Today's PMS clients, typically affluent or HNIs, are no longer satisfied with basic discretionary services,' Shah notes. 'They demand greater transparency, real-time visibility, and personalised strategies that are aligned with their financial goals. This shift has prompted PMS providers to upgrade digital capabilities, enhance client experience, and rethink relationship management.' This evolution is a direct reflection of a broader maturation in India's wealth management industry. Technology has been the great equalizer, dramatically lowering entry barriers by streamlining onboarding, reporting, and compliance. 'Resident investors can now be onboarded in less than 24 hours,' says Aashish P. Somaiyaa, Chief Executive Officer at WhiteOak Capital Asset Management. 'Digital documentation, e-signatures, and better KYC systems have removed much of the friction. While onboarding remains complex for NRIs and institutions, the broader direction is clearly positive.' The bedrock of belief: India's macroeconomic resilience This transformation isn't happening in a vacuum. It is anchored in the bedrock of India's macroeconomic resilience and stability. In just a decade, the nation has ascended from the world's 10th largest economy to fifth, doubling its GDP in the process. Unlike global peers grappling with debt, India has demonstrated consistent fiscal prudence. The country's fiscal deficit is projected to fall to 4.4% of GDP this fiscal year, down from 5.6% the year prior, all while building a formidable buffer of foreign exchange reserves. These sound fundamentals have cemented India's status as a premier long-term investment destination, bolstering the confidence of domestic investors who are now the primary drivers of the market. 'There has been a definitive shift in the maturity of India's investor base,' Somaiyaa observes. 'The surge in SIPs, especially among younger investors, signals a long-term, goal-oriented approach to investing. Domestic participation, both retail and institutional, has become the backbone of market flows, offering a buffer against foreign capital volatility.' A market powered by domestic ambition The result of this newfound domestic confidence is a capital market that is vibrant, deep, and increasingly self-reliant. India now accounts for nearly 10% of global IPO volumes—a remarkable feat in a world where listing activity in many developed markets has been sluggish. 'The strength of India's primary market is a clear reflection of supportive macro trends,' says Rahul Aggarwal, Indian Market and Product Specialist at Bloomberg. 'Indian firms, and increasingly even global players, are choosing to raise capital here, showing how vibrant and mature our public markets have become.' This maturity is also visible in the derivatives market, where participation from retail and proprietary traders has exploded. 'Since the pandemic, premium turnover in derivatives has jumped from $10 billion to over $150 billion per month,' Aggarwal adds. 'Retail participation has completely transformed the segment, though regulators are rightly tightening norms to ensure sustainability and mitigate risks.' However, this sustained bull run warrants a degree of caution. Nitin Chanduka, Equity Strategist at Bloomberg Intelligence, notes that while the fundamentals are strong, valuations are a key concern. 'The uptrend in Indian equities since the pandemic is the longest in the past two decades, fueled by premium consumption, surging manufacturing, and unprecedented domestic liquidity,' he shares. 'But record-high valuations and slowing top-line growth suggest there's little scope for earnings misses. This is a key risk to watch out for in 2025 as valuations remain expensive, notably in small and mid-cap segments.' The digital engine: technology as a core differentiator Underpinning all these trends is a technological revolution that has permeated every corner of financial services. From AI-powered quantitative research to seamless trade execution and integrated client reporting, digital transformation is now the central nervous system of modern investment management. 'Technology is no longer just an enabler; it's the engine of scale and efficiency,' says Shah of ICICI Prudential AMC. 'We're seeing growing adoption of AI in strategy development, particularly in quantitative investing, though the lack of consistent data remains a challenge. For now, the most effective use of AI is as a complementary layer to traditional research.' The next chapter in India's wealth story India's capital markets are in a state of historic transition—from being reliant on foreign capital to being domestically anchored, from product-centric to service-oriented, and from manual systems to digital-first operations. Within this paradigm shift, PMS and AIFs are emerging not merely as alternatives, but as mainstream vehicles for serious, sophisticated wealth creation. The road ahead will demand continuous innovation, robust risk management, and a relentless focus on the investor.
Business Wire
2 days ago
- Business Wire
Theraclion Growth Up in S1 2025
MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reviews its business for S1 2025. Sales of consumables (recurring revenue) up 30% compared to 2024 New treatment centers opened in Bulgaria and Spain Appointment of a new business manager and acceleration of commercial activities On-schedule completion of the follow-up period for the pivotal FDA clinical trial Martin Deterre, CEO of Theraclion, states: "In early 2025, Theraclion stepped up Sonovein's activity. In June, the final 12-month follow-ups for patients in the pivotal FDA-approved clinical trial were completed on-schedule. We are now awaiting the final results, which we expect to publish in September. Theraclion has also entered a business development phase: building a sales and marketing team, opening two new Sonovein treatment centers, and achieving significant growth in recurring revenue — all of which promise the achievement of our ambitious goals." Commercial activity acceleration As part of its business development, Theraclion is actively building its sales and marketing team. In May 2025, Thibault Le Normand joined the company as Chief Business Officer to boost sales in the Middle East and product placements (PPUs) of Sonovein in Europe. With over a decade of experience in international development of medical devices, Thibault Le Normand brings valuable expertise to this strategic growth phase. At the same time, the technological credibility and clinical maturity of Sonovein have been further demonstrated by the publication of new scientific articles as well as by over a dozen presentations at major international congresses by renowned physicians using the device. Sonovein's international profile has also increased through Theraclion's participation in congresses, such as Vein in Venice (April, Venice), Venous Symposium (May, New York), and the European Venous Forum (June, Krakow). This outreach effort was supported by the launch of a new product identity and a new website, giving Sonovein a new brand image that reflects innovation, clinical excellence, and ambition. In addition, two new product placement (PPU) contracts for Sonovein have been signed in Bulgaria and Spain, stepping up Theraclion's presence in Europe and expanding the installed base of the technology. Revenue for S1 2025 Theraclion's revenue for S1 2025 was €835K, up 89% compared to 2024 (€442K) (prior to the non-recurring adjustment of €680K related to the cancellation of Echopulse system sales in 2024). Consumables, which include recurring revenues from PPUs, was up 30% compared to S1 2024. Service revenues were up 232% over the same period. This strong momentum is a key indicator of increasing use of Sonovein by treatment centers and reflects the technology's sustained traction in the field. Combined, consumables and services — representing recurring revenue — was up 57% compared to 2024. Progress of the pivotal FDA clinical trial In the USA, the pivotal FDA-approved study for SONOVEIN® reached a major milestone in June 2025 with the on-schedule completion of the 12-month post-treatment patient follow-ups. Data analysis is currently underway, with results expected in September. Submission of the marketing authorization application to the FDA is planned for Fall 2025, with potential approval estimated for Q2 2026, subject to the FDA's processing time. This progress marks a critical strategic milestone in the work to access the world's largest market for venous disease treatment. Next financial publication: Theraclion will publish its interim financial results on October 29, 2025. About Theraclion Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and patients can immediately resume their routines. HIFU treatment concentrates therapeutic ultrasounds on an internal focal point from outside the body. Theraclion is developing SONOVEIN®, a CE-marked, a robotic platform for HIFU varicose vein treatment, which could replace millions of surgical procedures every year. In the USA, SONOVEIN® is an investigational device limited to investigational use; it is not available for sale in the USA. Based in Malakoff (Paris), the Theraclion team comprises some 30 people, most of them involved in technological and clinical development. Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI: 9695007X7HA7A1GCYD29
Yahoo
2 days ago
- Yahoo
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
CULVER CITY, Calif., July 25, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Piper Sandler & Co. is acting as the exclusive placement agent for the registered direct offering. The securities to be sold by the Company are offered under its automatic shelf registration statement on Form S-3 (Registration No. 333-278770). A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be available on the SEC's website at Electronic copies of the prospectus supplement may be obtained for free by contacting Piper Sandler & Co., 350 North 5th Street, Suite 1300, Minneapolis, MN 55402, Attention: Prospectus Department, or by telephone at (800) 747-3924, or by email at prospectus@ Before investing in this offering, interested parties should read the prospectus supplement, the accompanying prospectus and the other documents that are incorporated by reference in such prospectus supplement and the accompanying prospectus in their entirety. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About ImmunityBio, Inc. ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the timing and size of the proposed offering, the potential exercise of the warrants being offered and resulting additional proceeds to the Company, the anticipated closing of the equity financing described herein and use of proceeds to be received from such financing, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that reduce or eliminate the need for standard high-dose chemotherapy. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) whether the equity financing transaction described herein will close on the timeline anticipated, if at all, (ii) those related to the regulatory submission, filing and review process and the timing thereof, (iii) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (iv) whether clinical trials will result in registrational pathways, (v) whether clinical trial data will be accepted by regulatory agencies, (vi) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vii) potential delays in product availability, regulatory approvals, and reimbursement decisions, (viii) ImmunityBio's ability to retain and hire key personnel, (ix) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (x) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xi) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. View source version on Contacts Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio +1 Sign in to access your portfolio
